SWOT Analysis for Monopar Therapeutics Inc

30 Day SMA crossing over 200 Day SMA, and current price greater than open
Rising Momentum: Momentum Score Weekly Gainers
Companies with 10% increase in share price over three months, with rising net profit growth
High Normalized Momentum Score
Strong Momentum: Price above short, medium and long term moving averages
Relative Outperformance versus Industry over 1 Week
Rising Net Cash Flow and Cash from Operating activity
Relative Outperformance versus Industry over Half Year (6 Months)
Relative Outperformance versus Industry over the Quarter (3 Months)
Relative Outperformance versus Industry over 1 Year
Annual Profit Growth higher than Sector Profit Growth
PEG lower than Industry PEG
High Momentum Scores (Technical Scores greater than 50)
Relative Outperformance versus Industry over 1 Week
Company with No Debt
Annual Net Profits improving for last 2 years
Stock with Low PE (PE < = 10)
Highest Recovery from 52 Week Low
Stocks Outperforming their Industry Price Change in the Quarter

Stocks with Expensive Valuations according to the Trendlyne Valuation Score
Inefficient use of shareholder funds - ROE declining in the last 2 years
Inefficient use of assets to generate profits - ROA declining in the last 2 years
Top Losers
Low Piotroski Score : Companies with weak financials
Book Value Per Share deteriorating for last 2 years
Top Losers